India's Wockhardt says FDA alert affects potential sales of $100 mln
Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates
Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory partial-onset seizures
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Zalicus | 1 | 9 | 800 % |
| Circadian Technologies | 1 | 8 | 700 % |
| Agennix | 4 | 27 | 575 % |
| Vidacare | 1 | 6 | 500 % |
| BioDelivery Sciences | 1 | 6 | 500 % |
| Advanced Bionics | 2 | 12 | 500 % |
| AxoGen | 1 | 6 | 500 % |
| BioLife Solutions | 2 | 11 | 450 % |
| EffRx | 4 | 21 | 425 % |
| EarlySense | 2 | 10 | 400 % |